ImmunogenomicsID™ Comprehensive immunogenomic characterization ImmunogenomicsID™, the latest analytics component of the ACE ImmunoID platform, summarizes critical areas of tumor biology such as the antigen processing machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, and tumor escape. ImmunogenomicsID combines exome and transcriptome sequencing data from a paired tumor and normal [...]
Personalis, Inc. Launches Early Access Program for Cell-Free DNA ACE Exome for Tumor Neoantigens Menlo Park, CA – November 16, 2017 – Personalis, Inc., today announced the launch of an Early Access Program for its cell-free DNA (cfDNA) technology, which enables the detection of neoantigens across an exome (~20,000 genes) from a single [...]
The Fight Against Cancer: Neoantigens, Tumor Escape and the Tumor Microenvironment A conversation with JOHN WEST, CEO of Personalis, Inc. in Menlo, Park, California Nature, October 26, 2017 Tumours may be initiated by mutations in their driver genes, but their clinical outcomes are strongly influenced by the battle between [...]
Getting cancer vaccines right: Key challenges and solutions for neoantigen identification A conversation with Richard Chen, MD, CSO of Personalis, Inc. in Menlo, Park, California FierceBiotech, June 26, 2017 The promise of neoantigen-based cancer vaccines Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer. The development [...]
We use machine learning and neural networks to provide you with advanced analytics to better inform your discovery and translational research programs. Leveraging our enhanced exome and transcriptome, we’ve applied these assays for deeper bioinformatics analysis to accurately predict neoantigens. Using neoantigens as a predictor for determining likelihood of response to immunotherapies is one exciting [...]
Many clinical studies depend on tissue archives that have been fixed using FFPE procedures. This preservation process makes it difficult to obtain a pure sample and often leads to RNA degradation. To overcome this challenge, Personalis has developed an exome-capture transcriptome protocol based on our ACE Technology that allows us to produce high-quality transcriptome sequencing [...]
HLA binding is currently the most well-established criteria for ranking neoantigen candidates. Recent advances in training data generated from mass spectrometry, provide a larger dataset of peptide binders and non-binders for individual HLA alleles. This new binding data takes two important additional components into consideration: cleavage and transportation, which are critically important for presentation assessment. We leverage [...]
We use machine learning and neural networks to provide you with advanced analytics to better inform your discovery and translational research programs. ImmunogenomicsID guides the investigation of critical immuno-oncology genes with information including expression, variant effect impact, and DNA/RNA allelic fractions. Unlike targeted therapies, there tends to be general agreement that it is unlikely that [...]
Our CAP-accredited, CLIA-certified Laboratory is equipped with robots for efficient scale up, our custom Genomics Workflow Management System, Symphony, and the latest technology including Illumina NovaSeq Instruments to ensure your projects are delivered with reliable high quality and rapid timelines. Arrival: ACE ImmunoID requires paired tumor/normal analysis. The moment samples arrive at our CAP-accredited, CLIA-certified laboratory, [...]
Powered by our ACE Technology, our DNA Assays provide more uniform coverage at high depths than standard assays. Specifically, the ACE Cancer Exome outperforms conventional exome assays by enhances coverage across coding regions and supplementing more complex areas in the genomic architecture such as GC-rich content. The Personalis solution provides targeted sequencing to augment coverage [...]
